Actively Recruiting
Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer
Led by Nuvectis Pharma, Inc. · Updated on 2026-01-02
18
Participants Needed
3
Research Sites
75 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a multi-center, open label, Phase 1b study of NXP900 in combination with osimertinib in subjects with advanced, progressing, EGFR-mutated non-small cell lung cancer (NSCLC)
CONDITIONS
Official Title
Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Provide written informed consent.
- Be 18 years old or older.
- Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
- Have unresectable, metastatic, or locally advanced EGFR-mutated non-small cell lung cancer.
- Have prior treatment with osimertinib as first or second line, alone or with chemotherapy, in metastatic or locally advanced setting.
You will not qualify if you...
- Cancer has a known oncogenic driver alteration other than EGFR.
- Known EGFR mutations that cause resistance to osimertinib.
- Known overexpression of human epidermal growth factor receptor 2 (HER2).
- Any contraindications to treatment with osimertinib.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 3 locations
1
Massachusetts General Hospital
Boston, Massachusetts, United States, 02114
Not Yet Recruiting
2
NEXT Houston
Houston, Texas, United States, 77054
Actively Recruiting
3
NEXT Virginia
Fairfax, Virginia, United States, 22031
Actively Recruiting
Research Team
E
Erin Belshaw
CONTACT
S
Shay Shemesh
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here